Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:\r\n* Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3\r\n* History of acquired immune deficiency syndrome (AIDS) indicator conditions\r\n* Anti-retroviral therapy with any potent CYP3A4 inhibitor
Participants with persistently low CD4 counts less than 200 and a history of any acquired immune deficiency syndrome (AIDS)-defining infection in the last 6 months before screening are excluded from the study
Any patient with a history of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV) is excluded; subjects on immune suppressive therapy for organ transplant are also excluded
Active, known, or suspected immunosuppressive disorders, such as acquired or congenital immune deficiency syndromes and autoimmune diseases
Active uncontrolled infection, including known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Known infection with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) (testing not required).
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplatic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Acquired immune deficiency syndrome (AIDS) due to the potential for increased complications from treatment; note, however, that HIV testing is not required
Have known immune system disorders (including acquired immunodeficiency syndrome [AIDS], HIV infection or hepatitis B or C); eligible patients must have a negative HIV test result within 4 weeks prior to study initiation
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immune-compromised patients
Known to have lymphoma related to HIV or acquired immune deficiency syndrome (AIDS)
EXCLUSION - TREATMENT: Known primary immune deficiency or HIV positivity
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and those severely immunocompromised will be excluded; however, no patients will be tested for HIV
Presence of any condition or concurrent requirement for treatment with agents known to result in immune deficiency.
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Patients with known congenital or acquired immune deficiency (including those patients who require systemic immunosuppressant drugs for autoimmune disease or organ transplant)
Known Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Known history of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic hepatitis B or C.
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS] or other immune depressing disease); testing is not mandatory
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness
Immune deficiency: clinically significant primary or acquired immune deficiency (i.e. acquired immunodeficiency syndrome [AIDS] or on immunosuppressive medication after organ transplant)
Known human immunodeficiency virus positive (HIV[+]) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
Active uncontrolled infection, including known history of acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Immuosuppressive disorders (chronic steroid therapy, acquired or congenital immune deficiency syndromes, autoimmune disease)
Patients with a known immune deficiency
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
If there is clinical suspicion of acquired immune deficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test must be done within 42 days prior to registration; Note: HIV positive patients with a cluster of differentiation (CD)4+ T cell count > 200 per uL of blood and > 14% of all lymphocytes are eligible for this trial
Patients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the study
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Evidence of immune suppression due to: a) known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); b) known leukemia or lymphoma; c) those who require high dose steroids (> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment) or other immunosuppressive therapies (> 2 weeks); d) active hepatitis B or C; e) congenital or acquired cellular and/or humoral immune deficiency; f) other signs or symptoms of immune system suppression or concurrent opportunistic infection
Known positive testing for human immunodeficiency virus (HIV)or history of acquired immune deficiency syndrome (AIDS).
History of active primary immunodeficiency including, but not limited to acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be immunosuppressive; patients with known HIV, CD4 counts >= 200/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
The first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD)4 counts >= 350/mm^3 are allowed to participate if the following criteria are met:\r\n* Maintained on stable antiretroviral therapy with no significant drug interactions, and \r\n* No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (> 2 years from enrolling in trial), and \r\n* Physician providing patientâ€™s care for HIV must also approve of patient entering the study
Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking anti-retroviral therapy that may have a potential overlapping toxicity with the study therapy are not eligible
Human immunodeficiency virus (HIV) positive serology or acquired immune deficiency syndrome
Patients with immune deficiency are excluded
A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune\n             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as\n             determined by medical history.
Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study
Evidence of clinically significant immunosuppression such as organ or stem cell transplantation, any severe congenital or acquired cellular and/or humoral immune deficiency, concurrent opportunistic infection.
Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions (other than the presenting DLBCL) or post-transplant lymphoproliferative disorder (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV) on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior AIDS defining conditions and adequate CD4 count (> 400) are eligible
HIV positive patients with advanced immune suppression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non-lymphoma related death within 12-months due to other acquired immune deficiency syndrome (AIDS) complications should not be enrolled on the study
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; patients with known AIDS will be ineligible for this protocol; patients with clinical suspicion of AIDS and who are unwilling to have an HIV test are not eligible for this trial
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition
Evidence of immune suppression due to: \r\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\r\n* Known leukemia or lymphoma\r\n* Those who require high dose steroids or other immunosuppressive agents\r\n* Known hepatitis B or C infection \r\n* Congenital or acquired cellular and/or humoral immune deficiency\r\n* Other signs or symptoms of immune system suppression
Human immunodeficiency virus (HIV) infection without acquired immune deficiency syndrome (AIDS)-defining criteria are eligible
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
History or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia)
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, HIV testing is required for entry into this protocol due to the immunologic basis for induction treatment.
Known immune deficiency, including human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus positive (HIV)(+) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or known human immunodeficiency virus (HIV) seropositivity; note, however, that HIV testing is not required for entry into this protocol
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV); subjects on immune suppressive therapy for organ transplant
Human immune deficiency virus
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Prior chronic immune suppressive state (acquired immune deficiency syndrome [AIDS], immunosuppressive therapy)
History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that required systemic immunosuppression therapy and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immunodeficiency syndrome (AIDS), ongoing pregnancy, transplant immunosuppression)
Known chronic infectious disease including, but not limited to, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or other acquired or congenital disorder of the immune system
(2. continued) f) Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. g) Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], ongoing pregnancy, transplant immunosuppression)
For patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), the following must be true:\r\n* The patient is compliant on combination anti-retroviral therapy (CART)\r\n* The patient has cluster of differentiation (CD)4 count >= 200 at time of diagnosis
Serious uncontrolled infection; known human immunodeficiency virus (HIV)-seropositivity requiring retroviral therapy, or diagnosis of acquired immune deficiency syndrome (AIDS); diagnosis of chronic hepatitis B or C allowed
Conditions associated with increased susceptibility to infections with microorganisms; such conditions include, but are not limited to, acquired immune deficiency syndrome (AIDS), leukemia and intravenous (IV) drug abuse
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).
Human immunodeficiency virus (HIV)+/acquired immune deficiency syndrome (AIDS)
6. Subjects with known infection with human immunodeficiency virus or Acquired Immune Deficiency Syndrome (testing not required).
Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
History of immunosuppression, or conditions associated with congenital or acquired immune deficiency
Patients seropositive for the human immunodeficiency virus (HIV), and/or those who are taking anti-retroviral treatment for HIV/acquired immune deficiency syndrome (AIDS)
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known human immunodeficiency virus (HIV) positive or history of acquired immune deficiency syndrome (AIDS) or AIDS-defining illness
Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders;
Congenital or acquired immune deficiency at increased risk of infection.
Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Presence of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)
Patients with acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition or patients known to be human immunodeficiency virus (HIV) positive; note, however, that HIV testing is not required for entry into this protocol; the need to exclude these patients from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
Co-morbidity with immunosuppressive disease such as acquired immune deficiency syndrome (AIDS)
Positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Immune deficiency diseases such as immunoglobulin deficiency or immunosuppressive therapy that might interfere with appropriate immune response
Individuals who are immunosuppressed by virtue of medication or disease, as determined by the examining study physician; this includes acquired immune deficiency syndrome (AIDS) patients and subjects taking oral steroids
History or serologic evidence of chronic viral infection (hepatitis B or C), human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known history of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), hepatitis B or C.
Immune compromised individuals (human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS], immuno-suppressive drug therapy)
Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC (Centers for Disease Control) definition
